Replimune Group’s (REPL) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research report released on Tuesday,Benzinga reports. The firm currently has a $17.00 price target on the stock. HC Wainwright also issued estimates for Replimune Group’s Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

Several other brokerages also recently commented on REPL. Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $11.40 on Tuesday. The business has a 50-day moving average price of $11.44 and a two-hundred day moving average price of $9.50. Replimune Group has a 1-year low of $4.92 and a 1-year high of $12.97. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. The company has a market cap of $779.99 million, a P/E ratio of -3.74 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, analysts anticipate that Replimune Group will post -3.05 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in REPL. Millennium Management LLC lifted its position in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Braidwell LP boosted its stake in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Replimune Group during the first quarter valued at approximately $1,088,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.